



11,000 Results Any time ▾

Histone Deacetylases - PubMed Central (PMC)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873803>

May 03, 2013 - Histone deacetylases (HDACs) are one of the key players in the gene expression regulation network in cancer because of their repressive role on tumor suppressor genes. Higher expression and function of deacetylases disrupt the finely tuned acetylation homeostasis in both histone and non-histone target proteins.

Cited by: 62 Author: Sabnam Parbin, Swayamsiddha Kar, Aru...
Publish Year: 2014

Preclinical studies on histone deacetylase inhibitors as ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273414>

Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 2009; 280 (2):134-144. HDAC inhibitors can act both on cancer stem cells and the rest of the tumor cell mass, leading to complex biological outputs. As a note of caution, when used as single ...

Cited by: 12 Author: Brahma N. Singh, Hongyuan Zhou, Jinpin...
Publish Year: 2011

Histone deacetylases as new therapy targets for platinum ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4954831>

The biological function of histone deacetylases (HDACs) The MEF2 family of transcription factors is one of the important targets of class IIa HDACs. MEF2, major transcriptional activators for the expression of muscle-specific genes, also regulate other cellular programs, including neuronal survival, T cell apoptosis...

Cited by: 11 Author: Dmitri Pchejetski, Albandri Alfraidi, Keith ...
Publish Year: 2016

Combination Therapy With Histone Deacetylase Inhibitors ...

https://www.researchgate.net/publication/324088058_Combination_Therapy_With_Histone...

Mar 29, 2018 - HDACs are dysregulated in many cancers, making them a therapeutic target for the treatment of cancer. Histone deacetylase inhibitors (HDACi), a novel class of small-molecular therapeutics, are now ...

Histone Deacetylase Inhibitors as Anticancer Drugs ...

Histone deacetylase



Histone deacetylases are a class of enzymes that remove acetyl groups from an ϵ -N-acetyl lysine amino acid on a histone, allowing the histones to wrap the DNA more tightly. This is important because DNA is wrapped around histones, and DNA expression is regulated by acetylation and de-acetylation. Its action

is opposite to that of histone acetyltransferase. HDAC proteins are now also called lysine deacetylases, to describe their function rather than their target, which also includes non-histone proteins.



Data from: Wikipedia

[Suggest an edit](#)



12,300 Results

Any time ▾

Rational therapeutic combinations with histone deacetylase ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127396>

Histone deacetylase inhibitors potentiate topoisomerase I-mediated DNA damage, growth inhibition and cell death. Vorinostat **enhances** the effect of topotecan and SN-38 (the metabolite of irinotecan) in small-cell lung **cancer** and glioblastoma cells in vitro, respectively [55,56].

Cited by: 231 **Author:** K Ted Thurn, Scott Thomas, Amy Moore, P...

Publish Year: 2011

Histone deacetylase inhibitors (HDACIs): multitargeted ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584656>

Feb 25, 2013 - **Histone deacetylase (HDAC) inhibitors** are an emerging class of therapeutics with potential as anticancer drugs. The rationale for developing HDAC **inhibitors** (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addition to genetic mutations, epigenetic changes such as dysregulation of HDAC enzymes can alter phenotype and gene ...

Cited by: 229 **Author:** Katherine Ververis, Alison Hiong, Tom C Ka...

Publish Year: 2013

The Role of Histone Deacetylases in Prostate Cancer

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683066>

MS-275 exerts growth arrest and induces cell death in prostate **cancer** cell lines as well as inhibits the growth of subcutaneous xenografts. 123 HDAC **inhibitor** MS-275 restores the retinoid sensitivity in prostate **cancer** cells. 124 Further, it **enhances** the **histone** hyperacetylation and radiosensitivity of DU145 xenografts. 125 The exposure to MS ...

Cited by: 124 **Author:** Ata Abbas, Sanjay Gupta

Publish Year: 2008

Epigenetic targeting drugs potentiate chemotherapeutic ...

<https://www.nature.com/articles/s41598-017-04406-0>

Jun 22, 2017 · **Histone deacetylase (HDAC) inhibitor** LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung **cancer**. **Cancer Res** 66 , 11298–11304, doi ...

Cited by: 19 **Author:** Jingjing Li, Dapeng Hao, Li Wang, Haitao W...

Publish Year: 2017

Histone Deacetylase: An Epigenetic Target for Cancer ...

<https://www.vin.com/apputil/content/defaultadv1.aspx?pld=11262&id=3865583> ▾



12,200 Results

Any time ▾

[Rational therapeutic combinations with histone deacetylase ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127396>

Histone deacetylase inhibitors potentiate topoisomerase I-mediated DNA damage, growth inhibition and cell death. Vorinostat enhances the effect of topotecan and SN-38 (the metabolite of irinotecan) in small-cell lung cancer and glioblastoma cells in vitro, respectively [55,56].

Cited by: 235

Author: K Ted Thurn, Scott Thomas, Amy Moore, ...

Publish Year: 2011

[The Role of Histone Deacetylases in Prostate Cancer](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683066>

MS-275 exerts growth arrest and induces cell death in prostate cancer cell lines as well as inhibits the growth of subcutaneous xenografts. 123 HDAC inhibitor MS-275 restores the retinoid sensitivity in prostate cancer cells. 124 Further, it enhances the histone hyperacetylation and radiosensitivity of DU145 xenografts. 125 The exposure to MS ...

Cited by: 123

Author: Ata Abbas, Sanjay Gupta

Publish Year: 2008

[Epigenetic targeting drugs potentiate chemotherapeutic ...](#)

<https://www.nature.com/articles/s41598-017-04406-0>

Jun 22, 2017 · Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 66 , 11298–11304, doi ...

Cited by: 20

Author: Jingjing Li, Dapeng Hao, Li Wang, Haitao ...

Publish Year: 2017

[\(PDF\) Sodium Valproate, a Histone Deacetylase Inhibitor ...](#)

https://www.researchgate.net/publication/267814344_Sodium_Valproate_a_Histone...

Sodium Valproate, a Histone Deacetylase Inhibitor, Enhances the Efficacy of Vinorelbine-Cisplatin-based Chemoradiation in Non-small Cell Lung Cancer Cells

[Targeting Histone Demethylases in Cancer Therapy](#)

<https://www.researchgate.net/publication/40027641...>

Targeting Histone Demethylases in Cancer Therapy ... offer the potential to rapidly enhance the effectiveness of treatment for resistant cancers. ... and the pan-histone deacetylase inhibitor ...

3

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 52041

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Histone deacetylase inhibitor pretreatment enhances efficacy of DNA-interacting chemo-drugs in gastric cancer

Amnekar RV *et al.* Chromatin organization and chemotherapy response

Ramchandra V Amnekar, Shafqat A Khan, Mudasir Rashi, Bharat Khade, Rahul Thorat, Poonam Gera, Shailesh V Shrikhande, Duane T Smoot, Hassan Ashktorab, Sanjay Gupta

Abstract

BACKGROUND

The prognosis of gastric cancer continues to remain poor and epigenetic drugs

Match Overview

1	Crossref 26 words Nan Chen, Yi-Fan Peng, Yun-Feng Yao, Jin Gu. "Trans-anal minimally invasive surgery for rectal neoplasia"	1%
2	Internet 18 words crawled on 29-Dec-2016 clinicalepigeneticsjournal.biomedcentral.com	<1%
3	Internet 14 words crawled on 19-Oct-2019 f6publishing.blob.core.windows.net	<1%
4	Internet 13 words crawled on 03-Mar-2017 bmccancer.biomedcentral.com	<1%